Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska

Vaccine

Volumn 33, Issue 38, 2015, Pages 4813-4819

  Bruce, Michael G ^a   Singleton, Rosalyn ^b   Bulkow, Lisa ^a   Rudolph, Karen ^a   Zulz, Tammy ^a   Gounder, Prabhu ^a   Hurlburt, Debby ^a   Bruden, Dana ^a   Hennessy, Thomas ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b ALASKA NATIVE MEDICAL CENTER   (United States)

Author keywords

Alaska; Carriage; Invasive pneumococcal disease; Serotype; Streptococcus pneumoniae; US; Vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE;

ADOLESCENT; ADULT; ALASKA NATIVE; ARTICLE; CHILD; FEMALE; HEALTH IMPACT ASSESSMENT; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; UNITED STATES; VACCINATION; AGED; ALASKA; CLASSIFICATION; HETEROZYGOTE; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; PREVENTION AND CONTROL; STREPTOCOCCUS PNEUMONIAE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALASKA; CARRIER STATE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 84940718059     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.07.080     Document Type: Article

References (32)

1. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368(9546):1495-1502. [28.10.06].
2. National Notifiable Diseases Surveillance System. Available from: ; 2015. http://wwwn.cdc.gov/nndss/.
3. Pilishvili T., Lexau C., Farley M., Hadler J., Harrison L., Bennett N., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(1):32-41.
4. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP), 2010. Morbidity and mortality weekly report 2010;59(9):258-61.
5. Flannery B., Heffernan R., Harrison L., Ray S., Reingold A., Hadler J., et al. Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Inter Med 2006, 144(1):1-9.
6. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurlburt D.A., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA-J Am Med Assoc 2007 Apr 25, 297(16):1784-1792.
7. Bruce M., Deeks S., Zulz T., Bruden D., Navarro C., Lovgren M., et al. International circumpolar surveillance system for invasive pneumococcal disease, 1999-2005. Emerg Infect Dis 2008, 14(1):25-33.
8. Davidson M., Parkinson A.J., Bulkow L.R., Fitzgerald M.A., Peters H.V., Parks D.J. The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990-ethnic differences and opportunities for prevention. J Infect Dis 1994, 170(2):368-376. [August].
9. Rudolph K.M., Parkinson A.J., Reasonover A.L., Bulkow L.R., Parks D.J., Butler J.C. Serotype distribution and antimicrobial resistance patterns of invasive isolates of Streptococcus pneumoniae: Alaska, 1991-1998. J Infect Dis 2000, 182(2):490-496.
10. Rudolph K., Bruce M.G., Bulkow L., Zulz T., Reasonover A., Harker Jones M., et al. Molecular epidemiology of serotype 19A Streptococcus pneumoniae among invasive isolates from Alaska, 1986-2010. Int J Circumpolar Health 2013, 72.
11. Wenger J.D., Zulz T., Bruden D., Singleton R., Bruce M.G., Bulkow L., et al. Invasive pneumococcal disease in Alaskan children impact of the seven-valent pneumococcal conjugate vaccine and the role of water supply. Pediatr Infect Dis J 2010, 29(3):251-256. [March].
12. Bruden D.L., Hennessy T.W., Butler J.C., Hurlburt D.A., Parks D.J., Bulkow L.R. Evaluation of a volunteer sample in nasopharyngeal colonization surveys for Streptococcus pneumoniae in rural Alaska. Int J Circumpolar Health 2005, 64(1):16-25. [February].
13. Moore M.R., Hyde T.B., Hennessy T.W., Parks D.J., Reasonover A.L., Harker-Jones M., et al. Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska. J Infect Dis 2004, 190(11):2031-2038. [01.12.04].
14. Hammitt L.L., Bruden D.L., Butler J.C., Baggett H.C., Hurlburt D.A., Reasonover A., et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 2006, 193(11):1487-1494. [01.06.06].
15. Hennessy T.W., Singleton R.J., Bulkow L.R., Bruden D.L., Hurlburt D.A., Parks D., et al. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity. Vaccine 2005, 23(48-49):5464-5473. [01.12.05].
16. Gounder P., Bruce M., Bruden D.J.T., Singleton R., Rudolph K., Hurlburt D., et al. Effect of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae-Alaska, 2008-2012. J Infect Dis 2014, 209(8):1251-1258.
17. Miernyk K., Debyle C., Harker Jones M., Hummel K., Hennessy T., Wenger J., et al. Serotyping of Streptococcus pneumoniae isolates from nasopharyngeal samples: use of an algorithm combining microbiologic, serologic, and sequential multiplex PCR techniques. J Clin Microbiol 2011, 49(9):3209-3214.
18. Estimated Vaccination Coverage with 4 PCV Among Children 19-35 Months of Age by Race/Ethnicity and by State and Local Area-US, Nation Immunization Survey, 2013. Available from: http://www.cdc.gov/vaccines/imz-managers/coverage/nis/child/data/tables-2013.html#overall; 2013.
19. Singleton R., Wenger J., Klejka J., Bulkow L., Thompson A., Sarkozy D., et al. The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial. Pediatr Infect Dis J 2013, 32(3):257-263.
20. Zulz T., Wenger J., Rudolph K., Robinson D.A., Rakov A., Bruden D., et al. Molecular characterization of Streptococcus pneumoniae serotype 12F isolates associated with rural community outbreaks in Alaska. J Clin Microbiol 2013, 51(5):1402-1407.
21. Mosso K.L., Grant L.R., Weatherholtz R.C., Campbell J., Donaldson C., Dallas J., et al. Impact of 13-valent pneumococcal conjugate vaccine on a population at high risk for invasive pneumococcal disease. Pneumomia 2014, 3(ISPPD 2014):183.
22. Jayasinghe S., Chiu C., Menzies R., Bareja C., Krause V., McIntyre P. Early impact of 3+0 schedule of 13VPCV in Australian children and adults [abstract ISPPD-0429]. Pneumonia 2014, 3(ISPPD 2014):173.
23. Moore M., Taylor T., Pondo T., Barnes M., Petit S., Holtzman C., et al. Impact of 13-valent pneumococcal conjugate vaccine (pcv13) against invasive pneumococcal disease (IPD) among children <5 years old in the U.S. Pneumonia 2014, 3(ISPPD-9 Special Issue):149.
24. Iroh Tam P-Y., Madoff L., Coombes B., Pelton S. Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine. Pediatrics 2014, 134(2):210-217.
25. Mendes R., Costello A., Jacobs M., Biek D., Critchley I., Jones R. Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine. Diagn Microbiol Infect Dis 2014, 80(1):19-25.
26. Andrews N., Waight P., Burbidge P., Pearce E., Roalfe L., Zancolli M., et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis 2014, 14(9):839-846.
27. Kaye P., Malkani R., Slack M., Ladhani S., Borrow R., Andrews N., et al. Real-time surveillance to evaluate the impact of the pneumococcal conjugate vaccine (PCV) in England and Wales. Pneumonia 2014, 3:174.
28. Harboe Z., Dalby T., Weinberger D., Benfield T., M.Ãlbak Kr Slotved H., et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 2014, 59(8):1066-1073.
29. Guevara M., Ezpeleta C., Gil Setas A., Torroba L., Beristain X., Aguinaga A., et al. Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001-2013. Vaccine 2014, 32(22):2553-2562.
30. Phongsamart W., Srifeungfung S., Chatsuwan T., Nunthapisud P., Treerauthaweeraphong V., Rungnobhakhun P., et al. Changing trends in serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive diseases in Central Thailand, 2009-2012. Hum Vaccines Immunother 2014, 10(7).
31. van Hoek A., Sheppard C., Andrews N., Waight P., Slack M.P.E., Harrison T., et al. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine 2014, 32(34):4349-4355.
32. Dagan R., Patterson S., Juergens C., Greenberg D., Givon Lavi N., Porat N., et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis 2013, 57(7):952-962.